Neurocrine Biosciences: Hold Maintained as Analyst Lifts Price Target to $191 Amid Strong Ingrezza Demand and Pipeline Execution Risks

Sean Laaman, an analyst from Morgan Stanley, reiterated the Hold rating on Neurocrine. The associated price target was raised to $191.00.

Sean Laaman has given his Hold rating due to a combination of factors that balance strong fundamentals with valuation and execution risks. He acknowledges that Ingrezza’s first‑quarter performance, record new patient starts, and the expected boost from an expanded sales force point to demand that likely exceeds the company’s long‑term revenue guidance. At the same time, his view is that much of this upside is already reflected in the share price, even as he raises the official price target from $185 to $191 to capture higher projected earnings.

Laaman also highlights Crenessity as a key long‑term growth driver, noting its early but compelling launch in congenital adrenal hyperplasia and the prospect of significant adult penetration. However, he tempers this optimism with caution around the integration of the SLNO acquisition, the future commercial roll‑out of VYKAT XR, and the need to de‑risk late‑stage pipeline assets such as direclidine and osavampator. Taken together, these opportunities and uncertainties support a neutral stance, leading him to maintain a Hold recommendation despite a more constructive earnings and revenue outlook.

Laaman covers the Healthcare sector, focusing on stocks such as Neurocrine, Exelixis, and Halozyme. According to TipRanks, Laaman has an average return of 13.1% and a 59.13% success rate on recommended stocks.